CSLLY: AI 评分 48/100 — AI 分析 (4月 2026)

CSL Limited is a global biotechnology leader specializing in plasma-derived therapies and influenza vaccines. The company operates through CSL Behring and Seqirus, addressing critical unmet needs in immunology, hematology, and influenza prevention.

Key Facts: AI Score: 48/100 Sector: Healthcare

公司概况

概要：

CSL Limited, a global biotechnology company, develops and manufactures plasma-derived therapies and influenza vaccines. Operating through CSL Behring and Seqirus, the company addresses critical needs in immunology, hematology, and influenza prevention. With a strong market capitalization and dividend yield, CSL Limited maintains a robust presence in the global biopharmaceutical landscape.

CSLLY是做什么的？

Founded in 1916 in Melbourne, Australia, CSL Limited has evolved from a Commonwealth Serum Laboratories, a government organization focused on supplying vaccines to meet Australia's public health needs, into a global biotechnology leader. Today, CSL operates through two primary segments: CSL Behring and Seqirus. CSL Behring focuses on plasma-derived therapies, offering a range of products to treat immunodeficiency, bleeding disorders, hereditary angioedema, Alpha-1 antitrypsin deficiency, and neurological disorders. This segment also invests heavily in research and development of both plasma and non-plasma therapies. Seqirus, the second segment, manufactures and distributes non-plasma biotherapeutic products, with a primary focus on influenza vaccines. Seqirus is one of the world's largest influenza vaccine companies, dedicated to preventing seasonal and pandemic influenza. CSL's global reach extends to Australia, the United States, Germany, the United Kingdom, Switzerland, and China, among other countries. The company's commitment to innovation and patient care has solidified its position as a key player in the biopharmaceutical industry.

CSLLY的投资论点是什么？

CSL Limited presents a compelling investment case driven by its leadership in plasma-derived therapies and influenza vaccines. With a market capitalization of $94.60 billion and a P/E ratio of 33.10, the company demonstrates financial stability and growth potential. A dividend yield of 3.04% offers investors a steady income stream. Key growth catalysts include expanding its plasma collection network and developing innovative therapies. However, potential risks include regulatory challenges and competition from biosimilars. The company's strong profit margin of 9.2% and gross margin of 48.6% underscore its operational efficiency and pricing power. CSL's beta of 0.21 indicates lower volatility compared to the market, making it a relatively stable investment.

CSLLY在哪个行业运营？

CSL Limited operates within the biotechnology industry, a sector characterized by rapid innovation, stringent regulatory oversight, and high growth potential. The global biotechnology market is projected to reach trillions of dollars by 2026, driven by advancements in genomics, personalized medicine, and biopharmaceutical development. CSL competes with other major players such as ARGNF (Argenx SE), CHGCF (Chugai Pharmaceutical), CHGCY (Chugai Pharmaceutical), GLAXF (GlaxoSmithKline), and GNMSF (Genmab A/S). These companies vie for market share in plasma-derived therapies and vaccine development. The industry is also influenced by factors such as aging populations, increasing healthcare expenditure, and the growing prevalence of chronic diseases.

Biotechnology

Healthcare

CSLLY有哪些增长机遇？

Expansion of Plasma Collection Network: CSL Limited can drive growth by expanding its plasma collection network globally. Plasma-derived therapies are in high demand, and securing a stable supply of plasma is crucial. Investing in new collection centers and improving donor recruitment strategies will enhance CSL's production capacity and market share. The global plasma fractionation market is projected to reach $46.8 billion by 2027, presenting a significant opportunity for CSL to capitalize on this growing demand.
Development of Innovative Therapies: CSL Limited's growth can be fueled by investing in research and development to create innovative therapies for unmet medical needs. Focusing on areas such as immunology, hematology, and neurology, CSL can develop novel treatments that address critical health challenges. The biopharmaceutical market is driven by innovation, and CSL's ability to bring new products to market will be a key factor in its long-term success. This is an ongoing opportunity.
Geographic Expansion: CSL Limited can expand its presence in emerging markets to drive growth. Countries with growing healthcare systems and increasing access to medical treatments offer significant potential for CSL's products. By establishing partnerships, distribution networks, and manufacturing facilities in these regions, CSL can tap into new customer bases and revenue streams. This is an ongoing opportunity.
Strategic Acquisitions: CSL Limited can pursue strategic acquisitions to expand its product portfolio and market reach. Acquiring companies with complementary technologies or therapies can enhance CSL's competitive position and accelerate its growth. Identifying and integrating synergistic businesses will be crucial for CSL's long-term success. The biopharmaceutical industry is characterized by consolidation, and CSL's ability to execute successful acquisitions will be a key driver of its growth. This is an ongoing opportunity.
Enhancing Influenza Vaccine Portfolio: CSL Limited, through its Seqirus segment, can further enhance its influenza vaccine portfolio. Investing in research and development to create more effective and broadly protective influenza vaccines will be crucial. The global influenza vaccine market is projected to grow, driven by increasing awareness of the importance of vaccination and the ongoing threat of pandemic influenza. By developing innovative vaccines, CSL can capture a larger share of this market and improve public health outcomes. This is an ongoing opportunity.

Market capitalization of $94.60 billion reflects CSL Limited's significant presence in the biotechnology industry.
P/E ratio of 33.10 indicates investor confidence in the company's earnings potential.
Profit margin of 9.2% demonstrates CSL Limited's ability to generate profits from its operations.
Gross margin of 48.6% highlights the company's efficient cost management and pricing strategy.
Dividend yield of 3.04% provides investors with a consistent income stream.

CSLLY提供哪些产品和服务？

Researches and develops biopharmaceutical products.
Manufactures plasma-derived therapies for various medical conditions.
Markets and distributes its products globally.
Offers treatments for immunodeficiency disorders.
Provides therapies for bleeding disorders.
Develops and distributes influenza vaccines.
Conducts research on plasma and non-plasma therapies.

CSLLY如何赚钱？

Develops and manufactures plasma-derived therapies and influenza vaccines.
Sells its products to healthcare providers and patients through a global distribution network.
Invests in research and development to create new and innovative therapies.
Generates revenue through product sales, licensing agreements, and royalties.

Patients with immunodeficiency disorders.
Individuals with bleeding disorders.
People at risk of contracting influenza.
Healthcare providers and hospitals.
Government health agencies.

Proprietary plasma fractionation technology.
Strong brand reputation and customer loyalty.
Extensive global distribution network.
Significant investment in research and development.
Stringent regulatory approvals and high barriers to entry.

什么因素可能推动CSLLY股价上涨？

Ongoing: Expansion of plasma collection network to secure a stable supply of plasma for manufacturing plasma-derived therapies.
Ongoing: Investment in research and development to create innovative therapies for unmet medical needs.
Ongoing: Geographic expansion into emerging markets to tap into new customer bases and revenue streams.
Upcoming: Potential strategic acquisitions to expand product portfolio and market reach.
Ongoing: Enhancement of influenza vaccine portfolio through Seqirus segment to capture a larger share of the market.

CSLLY的主要风险是什么？

Potential: Changes in healthcare regulations could impact CSL Limited's ability to market and sell its products.
Ongoing: Competition from other biotechnology companies could erode CSL Limited's market share.
Potential: Supply chain disruptions could impact CSL Limited's ability to manufacture and distribute its products.
Potential: Economic downturns could reduce demand for CSL Limited's products.
Ongoing: Reliance on plasma supply exposes CSL to potential shortages and price fluctuations.

CSLLY的核心优势是什么？

Global leader in plasma-derived therapies.
Strong research and development capabilities.
Diverse product portfolio.
Established global distribution network.

CSLLY的劣势是什么？

Reliance on plasma supply.
Exposure to regulatory risks.
Competition from biosimilars.
Currency exchange rate fluctuations.

CSLLY有哪些机遇？

Expansion into emerging markets.
Development of innovative therapies.
Strategic acquisitions.
Increasing demand for plasma-derived therapies.

CSLLY面临哪些威胁？

Changes in healthcare regulations.
Competition from other biotechnology companies.
Supply chain disruptions.
Economic downturns.

CSLLY的竞争对手是谁？

Argenx SE — Focuses on developing antibody-based therapies. — (ARGNF)
Chugai Pharmaceutical — Develops and markets pharmaceutical products. — (CHGCF)
Chugai Pharmaceutical — Subsidiary of Roche, focusing on innovative pharmaceuticals. — (CHGCY)
GlaxoSmithKline — Global healthcare company with a broad range of products. — (GLAXF)
Genmab A/S — Specializes in antibody therapeutics for cancer. — (GNMSF)

Key Metrics

MoonshotScore: 48/100

Company Profile

CEO: Gordon Naylor DipCompSc
Headquarters: Melbourne, AU
Employees: 32,698
Founded: 2009

AI Insight

AI analysis pending for CSLLY

ADR Level: 1
ADR Ratio: 1:1
Home Market Ticker: CSLL

OTC Tier: OTC Other
Disclosure Status: Unknown

常见问题

What does CSL Limited do?

CSL Limited is a global biotechnology company that develops, manufactures, and markets plasma-derived therapies and influenza vaccines. Through its CSL Behring segment, the company offers treatments for immunodeficiency, bleeding disorders, and neurological disorders. The Seqirus segment focuses on influenza vaccines, providing protection against seasonal and pandemic influenza. CSL's products are used by healthcare providers and patients worldwide to treat and prevent life-threatening conditions.

What do analysts say about CSLLY stock?

Analyst consensus on CSLLY stock reflects a generally positive outlook, driven by the company's strong market position and growth prospects. Key valuation metrics, such as the P/E ratio and dividend yield, are closely monitored. Growth considerations include the expansion of the plasma collection network, development of innovative therapies, and geographic expansion. However, analysts also consider potential risks, such as regulatory challenges and competition from biosimilars. The overall sentiment suggests that CSLLY is a stable investment with long-term growth potential.

What are the main risks for CSLLY?

The main risks for CSLLY include regulatory challenges, competition from biosimilars, and reliance on plasma supply. Changes in healthcare regulations could impact the company's ability to market and sell its products. Competition from biosimilars could erode CSL's market share and pricing power. The company's reliance on plasma supply exposes it to potential shortages and price fluctuations. Additionally, economic downturns and supply chain disruptions could negatively impact CSL's financial performance.